Related Experiment Videos
Immune RNA therapy for renal cell carcinoma: survival and immunologic monitoring
Abstract:
Twenty patients with metastatic renal cell carcinoma and nine patients with minimal residual disease (MRD) but at high risk for recurrence following nephrectomy received weekly four milligram intradermal injections of purified RNA extracted from lymphoid organs of sheep immunized with human renal cell carcinoma. Eighty-six consecutive UCLA patients with metastatic renal cell carcinoma served as retrospective controls. Survival between subpopulations in each group matched by computer according to extent and location of metastases, age, sex, and interval between nephrectomy and occurrence of metastases were compared by Life Table Analysis. Survival was significantly greater in RNA-treated patients (P < .05) who had multiple metastases limited to the lungs when compared with matched controls. RNA therapy did not influence survival of patients with metastases to other sites (bone, brain, liver, lymph nodes, or skin) or multiple organ involvement. All nine MRD patients treated with RNA remained free of recurrence for a mean observation period of 18 months, range ten to 34 months. No significant toxicity was observed. Changes in skin test responses were related primarily to tumor burden. Increased lymphocyte mediated cytotoxicity in RNA recipients was associated with a somewhat improved survival period. Changes in absolute lymphocyte counts had no correlation with clinical course, and complement fixing antibody generally decreased after excision of tumor, was absent in patients with progression, and was present in low levels in patients with a favorable clinical response. RNA therapy may be of value in selected patients with metastatic renal cell carcinoma, and as an adjunct to definitive surgery.
Insights
RNA therapy showed improved survival in select metastatic renal cell carcinoma patients with lung-limited metastases. Minimal residual disease patients remained recurrence-free, with no significant toxicity observed.
Area of Science:
- Immunotherapy
- Oncology
- Biotechnology
Background:
- Metastatic renal cell carcinoma (mRCC) presents a significant clinical challenge.
- Effective treatments for mRCC, especially for patients with minimal residual disease (MRD), are needed.
Purpose of the Study:
- To evaluate the efficacy and safety of intradermal purified RNA injections in patients with mRCC and high-risk MRD.
- To assess the impact of RNA therapy on patient survival and recurrence rates.
Main Methods:
- Weekly intradermal injections of purified sheep RNA (4 mg) administered to 20 mRCC and 9 MRD patients.
- Retrospective comparison with 86 mRCC control patients matched for clinical and demographic factors.
- Life Table Analysis used to compare survival between RNA-treated and control groups.
Main Results:
- Significantly improved survival in RNA-treated mRCC patients with lung-limited metastases (P < .05).
- No survival benefit observed for RNA therapy in patients with metastases to other sites or multiple organ involvement.
- All 9 MRD patients remained recurrence-free for a mean of 18 months post-treatment.
- Increased lymphocyte-mediated cytotoxicity correlated with improved survival; no significant toxicity noted.
Conclusions:
- RNA therapy may benefit selected mRCC patients, particularly those with lung-limited metastases.
- RNA therapy shows promise as an adjunct to surgery for MRD patients, preventing recurrence.
- Further investigation into RNA therapy for renal cell carcinoma is warranted.